MicroRNA biomarkers in glioblastoma

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Resumé

Recent research suggests that deregulation of microRNAs (miRNAs) is involved in initiation and progression of many cancers, including gliomas and that miRNAs hold great potential as future diagnostic and therapeutic tools in cancer. MiRNAs are a class of short non-coding RNA sequences (18-24 nucleotides), which base-pair to target messenger RNA (mRNA) and thereby cause translational repression or mRNA degradation based on the level of complementarity between strands. Profiling miRNAs in clinical glioblastoma samples has shown aberrant expression of numerous miRNAs when compared to normal brain tissues. Understanding these alterations is key to developing new biomarkers and intelligent treatment strategies. This review presents an overview of current knowledge about miRNA alterations in glioblastoma while focusing on the clinical future of miRNAs as biomarkers and discussing the strengths and weaknesses of various methods used in evaluating their expression.
OriginalsprogEngelsk
TidsskriftJournal of Neuro-Oncology
Vol/bind114
Udgave nummer1
Sider (fra-til)13-23
Antal sider11
ISSN0167-594X
DOI
StatusUdgivet - aug. 2013

Fingeraftryk

Glioblastoma
MicroRNAs
Untranslated RNA
Messenger RNA
Glioma
Base Pairing
Neoplasms
Research

Citer dette

@article{7dddadf5d2ff4ef180497f7b542e8975,
title = "MicroRNA biomarkers in glioblastoma",
abstract = "Recent research suggests that deregulation of microRNAs (miRNAs) is involved in initiation and progression of many cancers, including gliomas and that miRNAs hold great potential as future diagnostic and therapeutic tools in cancer. MiRNAs are a class of short non-coding RNA sequences (18-24 nucleotides), which base-pair to target messenger RNA (mRNA) and thereby cause translational repression or mRNA degradation based on the level of complementarity between strands. Profiling miRNAs in clinical glioblastoma samples has shown aberrant expression of numerous miRNAs when compared to normal brain tissues. Understanding these alterations is key to developing new biomarkers and intelligent treatment strategies. This review presents an overview of current knowledge about miRNA alterations in glioblastoma while focusing on the clinical future of miRNAs as biomarkers and discussing the strengths and weaknesses of various methods used in evaluating their expression.",
keywords = "Biological Markers, Brain Neoplasms, Gene Expression Regulation, Neoplastic, Glioblastoma, Humans, MicroRNAs",
author = "Hermansen, {Simon Kj{\ae}r} and Kristensen, {Bjarne Winther}",
year = "2013",
month = "8",
doi = "10.1007/s11060-013-1155-x",
language = "English",
volume = "114",
pages = "13--23",
journal = "Journal of Neuro-Oncology",
issn = "0167-594X",
publisher = "Springer",
number = "1",

}

MicroRNA biomarkers in glioblastoma. / Hermansen, Simon Kjær; Kristensen, Bjarne Winther.

I: Journal of Neuro-Oncology, Bind 114, Nr. 1, 08.2013, s. 13-23.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

TY - JOUR

T1 - MicroRNA biomarkers in glioblastoma

AU - Hermansen, Simon Kjær

AU - Kristensen, Bjarne Winther

PY - 2013/8

Y1 - 2013/8

N2 - Recent research suggests that deregulation of microRNAs (miRNAs) is involved in initiation and progression of many cancers, including gliomas and that miRNAs hold great potential as future diagnostic and therapeutic tools in cancer. MiRNAs are a class of short non-coding RNA sequences (18-24 nucleotides), which base-pair to target messenger RNA (mRNA) and thereby cause translational repression or mRNA degradation based on the level of complementarity between strands. Profiling miRNAs in clinical glioblastoma samples has shown aberrant expression of numerous miRNAs when compared to normal brain tissues. Understanding these alterations is key to developing new biomarkers and intelligent treatment strategies. This review presents an overview of current knowledge about miRNA alterations in glioblastoma while focusing on the clinical future of miRNAs as biomarkers and discussing the strengths and weaknesses of various methods used in evaluating their expression.

AB - Recent research suggests that deregulation of microRNAs (miRNAs) is involved in initiation and progression of many cancers, including gliomas and that miRNAs hold great potential as future diagnostic and therapeutic tools in cancer. MiRNAs are a class of short non-coding RNA sequences (18-24 nucleotides), which base-pair to target messenger RNA (mRNA) and thereby cause translational repression or mRNA degradation based on the level of complementarity between strands. Profiling miRNAs in clinical glioblastoma samples has shown aberrant expression of numerous miRNAs when compared to normal brain tissues. Understanding these alterations is key to developing new biomarkers and intelligent treatment strategies. This review presents an overview of current knowledge about miRNA alterations in glioblastoma while focusing on the clinical future of miRNAs as biomarkers and discussing the strengths and weaknesses of various methods used in evaluating their expression.

KW - Biological Markers

KW - Brain Neoplasms

KW - Gene Expression Regulation, Neoplastic

KW - Glioblastoma

KW - Humans

KW - MicroRNAs

U2 - 10.1007/s11060-013-1155-x

DO - 10.1007/s11060-013-1155-x

M3 - Journal article

VL - 114

SP - 13

EP - 23

JO - Journal of Neuro-Oncology

JF - Journal of Neuro-Oncology

SN - 0167-594X

IS - 1

ER -